To the Editor: In August 2019, the Australian Institute of Health and Welfare (AIHW) released a report on chronic musculoskeletal conditions in Australia.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Australian Institute of Health and Welfare. Arthritis [Cat. No. PHE 234]. Canberra: AIHW, 2019. https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/arthritis/related-material (viewed Jan 2019).
- 2. Pisaniello HL, Lester S, Gonzalez‐Chica D, et al. Gout prevalence and predictors of urate‐lowering therapy use: results from a population‐based study. Arthritis Res Ther 2018; 20: 143.
- 3. Rai SK, Choi HK, Choi SHJ, et al. Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies. Rheumatology (Oxford) 2018; 57: 1282–1292.
- 4. Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricaemia and Crystal‐Associated Disease Network (G‐CAN) consensus statement regarding labels and definitions of disease states of gout. Ann Rheum Dis 2019; 78: 1592–1600.
- 5. Dalbeth N, Schumacher HR, Fransen J, et al. Survey definitions of gout for epidemiologic studies: comparison with crystal identification as the gold standard. Arthritis Care Res (Hoboken) 2016; 68: 1894–1898.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Nicola Dalbeth reports grants and personal fees from AstraZeneca, grants from Amgen, and personal fees from Dyve, Hengrui, Horizon, Abbvie, Pfizer, and Janssen outside the submitted work. Helen Keen reports personal fees from Abbvie, Cornerstones, Roche, and Pfizer outside of the submitted work.